(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumerationExpands CNSide contracted payer ...
Molecular diagnostics are specialized tests doctors use to look at proteins, RNA, and DNA in and on cancer cells. When you have breast cancer, they show your doctors what’s unique about your tumor so ...
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted ...
A new review warns that the molecular tests defining modern glioma diagnosis remain out of reach for most of the world, and ...
Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C. Co-Diagnostics and ReadyGo target decentralized Ebola detection as th ...
Sharpen pricing, prioritize molecular diagnostics and genomics, and guide R&D and investment amid point-of-care and self-testing disruption.Dublin, Oct. 09, 2026 (GLOBE NEWSWIRE) -- "Clinical Medical ...
New automation platform brings open, AI-assisted automation to molecular microbiology and NGS workflows, with configurations from €50,000 to €90,000 WOIPPY, FRANCE, October 5, 2026 /EINPresswire.com/ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results